Cancer Immunotherapy

Myelodysplastic Syndrome

Immunotherapy in the form of an immunomodulator is approved in some instances to treat transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a 5q chromosomal abnormality with or without cytogenetic abnormalities (see The Lymphatic System). This immunomodulator is given orally.

PreviousNext